Merck (MRK) Asset Writedowns and Impairment (2010 - 2023)

Merck (MRK) has reported Asset Writedowns and Impairment for 14 consecutive years, with $779.0 million the latest figure, recorded in Q4 2023.

• On a quarterly basis, Asset Writedowns and Impairment fell 7.15% year-over-year to $779.0 million in Q4 2023; TTM through Dec 2023 was $2.8 billion, a 38.41% increase from a year earlier, with the FY2025 full-year figure at $55.0 million, up 41.03% from the prior year.
• Asset Writedowns and Impairment was $779.0 million for Q4 2023 at Merck, down from $839.0 million in the prior quarter.
• Over five years, Asset Writedowns and Impairment peaked at $1.7 billion in Q4 2020 and troughed at $15.0 million in Q3 2020.
• A 5-year average of $505.9 million and a median of $302.0 million in 2021 frame the typical range for Asset Writedowns and Impairment.
• The widest YoY moves for Asset Writedowns and Impairment: up 856.25% in 2020, down 97.55% in 2020.
• Over 5 years, Asset Writedowns and Impairment stood at $176.0 million in 2019, then jumped by 856.25% to $1.7 billion in 2020, then sank by 82.06% to $302.0 million in 2021, then surged by 177.81% to $839.0 million in 2022, then retreated by 7.15% to $779.0 million in 2023.
• The last three Asset Writedowns and Impairment figures came in at $779.0 million (Q4 2023), $839.0 million (Q4 2022), and $887.0 million (Q3 2022), per Business Quant data.